AMRI (AMRI) Announces Second Compound from Bristol-Myers (BMY) Agreement Will Move Into Preclinical Development
Tweet Send to a Friend
AMRI (NASDAQ: AMRI) announced today that a second compound being developed under its license and research agreement with Bristol-Myers Squibb ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
